EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/ β -Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers

Natalia Yu Anisimova, Andrey V Sosnov, Nadezhda E Ustyuzhanina, Gianfranco Baronzio, Mikhail V Kiselevsky

ISRN Oncology · 2011

DOI: 10.5402/2011/405656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Oncology, 2011. Verfasst von Natalia Yu Anisimova und 4 weiteren Autor:innen. Beteiligte Einrichtung: N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Kashirskoe Shosse, 24, Moscow 115478, Russia. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanocomposition comprised of interleukin-2 in suboptimal noneffective concentration and β -cyclodextrin was studied in vitro . This preparation as well as interleukin-2 in optimal concentration was shown to increase natural killer activity to K-562 cells and cytotoxicity of activated peripheral blood mononuclear cells (PBMCs) against PC-3 and DU 145 cells. At the same time β -cyclodextrin or interleukin-2 in equimolar concentrations did not influence the spontaneous killer activity of PBMC. This combination of cyclodextrin + interleukin-2 led to the decrease of interleukin-2 effective concentration by an order. This phenomenon could be explained by cyclodextrins ability to promote the formation of nanoparticles with drugs, which results in enhancing their water solubility and bioavailability. Besides, interleukine-2/ β -cyclodextrin nanocomposition as opposed to interleukin-2 alone led to increasing the number of not only lymphocytes, but also macrophages contained in activated PBMC population. Application of low concentration of interleukin-2 allowing for good clinical efficiency may significantly mitigate the side effects of the drug and enable to develop adoption of immunotherapy for patients with androgen-resistant prostate cancer.

Autor:innen und Institutionen

  • N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Kashirskoe Shosse, 24, Moscow 115478, Russia.

Zitieren

APA

Anisimova, N. Y., Sosnov, A. V., Ustyuzhanina, N. E., Baronzio, G., & Kiselevsky, M. V. (2011). Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/ β -Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers. ISRN Oncology. https://doi.org/10.5402/2011/405656

Vancouver

Anisimova NY, Sosnov AV, Ustyuzhanina NE, Baronzio G, Kiselevsky MV. Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/ β -Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers. ISRN Oncology. 2011. doi:10.5402/2011/405656

BibTeX
@article{Anisimova2011,
  author = {Anisimova, Natalia Yu and Sosnov, Andrey V and Ustyuzhanina, Nadezhda E and Baronzio, Gianfranco and Kiselevsky, Mikhail V},
  title = {Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/ β -Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers},
  journal = {ISRN Oncology},
  year = {2011},
  doi = {10.5402/2011/405656}
}
Kostenlos starten →